Molecular Imaging, Inc. Featured in May 15th Genetic Engineering & Biotechnology News
According to Dr. McConville, MII uses a full range of imaging modalities for anatomical, functional, and molecular outputs, enabling the company to provide their customers with combined pharmacology and imaging biomarkers that assist in their go/no-go decision-making process. The increasing reliance on imaging in the pharmaceutical industry as well as parallel improvements in the technology has enabled MI to add a broad base of imaging assays.
Read the full article at http://www.genengnews.com/gen-articles/cro-capabilities-expand-to-suit-client-needs/4113/